Last edition
News about "GLP-1 receptor agonist "
Japan Approves Wegovy for MASH
Wegovy subcutaneous injection has been approved in Japan for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), becoming the first approved therapy for the disease in the country.
GLP-1 Receptor Agonist | 22/06/2026 | By News Bureau
Lilly's Oral GLP-1 Foundayo Shows Superior A1C Control and Weight Loss in Type 2 Diabetes
Lilly’s oral GLP-1 drug Foundayo (orforglipron) delivered superior A1C control and weight loss in 3 pivotal Type 2 Diabetes (T2D) trials, outperforming oral semaglutide and helping more patients achieve glycemic targets.
GLP-1 Receptor Agonist | 10/06/2026 | By News Bureau | 102
Novo Nordisk's Zenagamtide Delivers Up to 14.6 Percent Weight Loss in Type 2 Diabetes
Novo Nordisk’s investigational once-weekly therapy zenagamtide demonstrated significant A1C reductions and up to 14.6 percent weight loss in adults with Type 2 Diabetes in a phase 2 trial presented at ADA 2026. The strong results support advancement of zenagamtide into phase 3 clinical development.
GLP-1 Receptor Agonist | 08/06/2026 | By News Bureau
Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing
Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.
GLP-1 Receptor Agonist | 08/06/2026 | By News Bureau
Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE, First Market Outside the US
UAE becomes first country outside the United States to offer the oral semaglutide treatment for obesity, marking a key step in Novo Nordisk’s global expansion plans.
GLP-1 Receptor Agonist | 04/06/2026 | By News Bureau
Dr. Reddy's Launches Oral Semaglutide Biosimilar Obeda Tablets in India
Dr. Reddy's launches Obeda oral semaglutide tablets in India, strengthening its GLP-1 portfolio after recent generic semaglutide injection launches in India and Canada for diabetes and obesity care.
GLP-1 Receptor Agonist | 20/05/2026 | By News Bureau | 169
Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting
Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.
GLP-1 Receptor Agonist | 09/04/2026 | By News Bureau | 198
Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
GLP-1 Receptor Agonist | 30/12/2025 | By News Bureau | 199
Eli Lilly Reports Positive Phase 3 Topline Results for Oral GLP-1 Orforglipron in Type 2 Diabetes
Eli Lilly and Company has announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials evaluating orforglipron for the treatment of type 2 diabetes.
GLP-1 Receptor Agonist | 16/10/2025 | By Dineshwori | 401
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy